Syndrome News and Research

RSS

Carcinogenesis is just another form of speciation, proposes new theory

Cancer patients may view their tumors as parasites taking over their bodies, but this is more than a metaphor for Peter Duesberg, a molecular and cell biology professor at the University of California, Berkeley.

27 Jul 2011

Virtual reality study to address alcohol abuse issues in veterans

The spoils of war for returning veterans may include addictions, injury and the constant images of horrific events they witnessed. Now a University of Houston joint study funded by the Veterans Health Administration Rehabilitation Research and Development service looks to address these issues through the use of virtual reality.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Watson second quarter net revenue increases 24% to $1.1 billion

Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the second quarter ended June 30, 2011, an increase of 24 percent when compared to $875.3 million in the second quarter 2010.

26 Jul 2011

Patients with MTBI exhibit abnormal functional connectivity in the thalamus

A new study has found that patients with mild traumatic brain injury (MTBI) exhibit abnormal functional connectivity in the thalamus, a centrally located relay station for transmitting information throughout the brain.

26 Jul 2011

Tumor marker, endoscopic ultrasound more likely to detect stage 1 pancreatic cancer

Researchers from New England report in a new study that using a tumor marker, serum CA 19-9, combined with an endoscopic ultrasound if the tumor marker is elevated, is more likely to detect stage 1 pancreatic cancer in a high-risk population than by using the standard means of detection.

26 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011

Fragile X syndrome study to reveal more

Fragile X syndrome is the most common inherited cause of intellectual disability in the world. Medical experts, including the Mater Hospital's Dr Helen Heussler, are today launching a new push to uncover the secrets of a disorder that affects a child born in Australia every week. Fragile X is passed from parent carriers who often exhibit very few symptoms. Estimates suggest more than 100,000 Australians either carry the gene mutation that causes Fragile X or have the syndrome, yet the vast majority have not been diagnosed, according to the Fragile X Association of Australia.

25 Jul 2011

Intravenous fluids appear to lower severity of kidney failure in children with E. coli infection

Infection with E. coli bacteria can wreak havoc in children, leading to bloody diarrhea, fever and kidney failure. But giving children intravenous fluids early in the course of an E. coli O157:H7 infection appears to lower the odds of developing severe kidney failure, according to researchers at Washington University School of Medicine in St. Louis and other institutions.

25 Jul 2011

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

22 Jul 2011

Insight into Fragile X Syndrome and autism

Researchers now have a much clearer understanding of how mutations in a single gene can produce the complex cognitive deficits characteristic of Fragile X Syndrome, the most common inherited form of intellectual disability.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Metabolic syndrome linked to increased risk of primary liver cancers

22 Jul 2011

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris of $185.7 million in Q2, reflecting steady addition of new patients, compared to $125.8 million for the same period in 2010.

21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Essential criteria for clinical diagnosis of restless legs syndrome

We've all experienced abnormal sensations in our legs at one time or another, but for as many as 10 percent of the US population, restless legs syndrome (RLS) is a daily occurrence. Characterized by throbbing, pulling, tingling, itching, and crawling sensations, RLS is a neurological disorder that produces unpleasant physical sensations in the extremities and an urge to counteract that sensation by movement.

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta

The U.S. Food and drug Administration (FDA) has finally approved AstraZeneca's Brilinta blood thinner for patients with acute coronary syndrome - conditions, such as heart attack and angina.

20 Jul 2011

Speed and efficiency of response to outbreaks are key to tackling epidemics

In an age where the next pandemic could leap continents in the hours it takes for an international flight to take off and land, University of Utah Professor Paul Hu fears the death toll may depend on how fast and efficiently world health officials can respond to an outbreak.

20 Jul 2011